HRMY 📈 Harmony Biosciences Holdings - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US4131971040
HRMY: Sleep, Narcolepsy, Daytime, Pharmaceuticals, Neurological, Therapies
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania. Web URL: https://www.harmonybiosciences.com
Additional Sources for HRMY Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
HRMY Stock Overview
| Market Cap in USD | 1,842m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2020-08-19 |
HRMY Stock Ratings
| Growth 5y | -3.43% |
| Fundamental | 79.1% |
| Dividend | - |
| Rel. Strength Industry | 68 |
| Analysts | 4/5 |
| Fair Price Momentum | 31.21 USD |
| Fair Price DCF | 99.88 USD |
HRMY Dividends
No Dividends PaidHRMY Growth Ratios
| Growth Correlation 3m | -43.1% |
| Growth Correlation 12m | 58% |
| Growth Correlation 5y | -23% |
| CAGR 5y | -1.79% |
| CAGR/Mean DD 5y | -0.06 |
| Sharpe Ratio 12m | 0.26 |
| Alpha | -16.30 |
| Beta | 0.79 |
| Volatility | 46.06% |
| Current Volume | 317.6k |
| Average Volume 20d | 572.8k |
What is the price of HRMY stocks?
As of December 30, 2024, the stock is trading at USD 34.20 with a total of 317,610 shares traded.
Over the past week, the price has changed by -2.15%, over one month by -1.36%, over three months by -14.50% and over the past year by +5.88%.
As of December 30, 2024, the stock is trading at USD 34.20 with a total of 317,610 shares traded.
Over the past week, the price has changed by -2.15%, over one month by -1.36%, over three months by -14.50% and over the past year by +5.88%.
Is Harmony Biosciences Holdings a good stock to buy?
Yes, based on ValueRay Fundamental Analyses, Harmony Biosciences Holdings (NASDAQ:HRMY) is currently (December 2024) a good stock to buy. It has a ValueRay Fundamental Rating of 79.08 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of HRMY as of December 2024 is 31.21. This means that HRMY is currently overvalued and has a potential downside of -8.74%.
Yes, based on ValueRay Fundamental Analyses, Harmony Biosciences Holdings (NASDAQ:HRMY) is currently (December 2024) a good stock to buy. It has a ValueRay Fundamental Rating of 79.08 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of HRMY as of December 2024 is 31.21. This means that HRMY is currently overvalued and has a potential downside of -8.74%.
Is HRMY a buy, sell or hold?
Harmony Biosciences Holdings has received a consensus analysts rating of 4.00. Therefor, it is recommend to buy HRMY.
Harmony Biosciences Holdings has received a consensus analysts rating of 4.00. Therefor, it is recommend to buy HRMY.
- Strong Buy: 4
- Buy: 3
- Hold: 0
- Sell: 2
- Strong Sell: 0
What are the forecast for HRMY stock price target?
According to ValueRays Forecast Model, HRMY Harmony Biosciences Holdings will be worth about 34.3 in December 2025. The stock is currently trading at 34.20. This means that the stock has a potential upside of +0.41%.
According to ValueRays Forecast Model, HRMY Harmony Biosciences Holdings will be worth about 34.3 in December 2025. The stock is currently trading at 34.20. This means that the stock has a potential upside of +0.41%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 49.5 | 44.7% |
| Analysts Target Price | 42.9 | 25.4% |
| ValueRay Target Price | 34.3 | 0.4% |